Labcorp to Introduce Combined Oncology Offering at 2021 ASCO® Annual Meeting
03 June 2021 - 7:20AM
Business Wire
Presentation Features Labcorp’s Combined
Oncology Diagnostic and Drug Development Platform for Clinicians
and Biopharmaceutical Companies
Labcorp (NYSE: LH), a leading global life sciences company,
today announced the introduction of its combined Labcorp oncology
platform at the virtual 2021 American Society of Clinical Oncology
(ASCO®) Annual Meeting held June 4-8.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210602006067/en/
(Photo courtesy of Labcorp)
Labcorp’s oncology platform brings together the company’s
leadership in diagnostic testing with its comprehensive drug
development services, delivering targeted solutions for oncology by
leveraging breakthrough science and insights from clinical and
patient data to power better decisions and improved patient
outcomes. Labcorp’s highly trained and specialized oncology team is
led by Prasanth Reddy, M.D., MPH, a triple-board certified
oncologist, and includes Robert Phillips, Ph.D., vice president and
head of enterprise oncology.
“Advances in science have led to promising cancer-related
discoveries, yet there is much more to do to in the field of
oncology to find better treatments and improve lives,” said
Phillips. “Labcorp has a history of developing best-in-class
diagnostics and drug development solutions that can help accelerate
new therapy options for cancer patients. We are able to empower
better decisions and make precision medicine available to more
cancer patients by expanding access to diagnostic testing and
clinical trial opportunities across communities.”
Phillips will speak as part of the Industry Expert Theater1 on
Monday, June 7, from 10-10:40 a.m. EDT. His presentation,
Reimagining Precision Medicine Throughout a Patient's Journey, will
introduce the Labcorp oncology platform and highlight new, expanded
testing and trial options. Immediately following the presentation,
Phillips will be conducting a live audience Q&A session.
Attendees will also have on-demand access to the presentation for
the duration of the conference. Labcorp’s online exhibit for the
ASCO Annual Meeting is available 24/7 between Friday, May 14, and
Tuesday, July 6. The exhibit aims to educate attendees on testing
options offered by Labcorp, as well as the wide-ranging support the
company provides for oncology clinical trials. Attendees will be
able to leave a virtual business card at the exhibit page to
connect with Labcorp. To access the online exhibit and Dr.
Phillips’ presentation, and to learn more about the conference,
please visit https://conferences.asco.org/am/attend.
Labcorp’s comprehensive oncology test menu to be discussed at
the ASCO Annual Meeting includes the commercial introduction of
OmniSeq® INSIGHT—a pan-cancer, tissue-based sequencing test for
patients with late-stage solid tumor cancers. The test helps
physicians make decisions about therapeutic treatments and identify
patients who may be eligible for any of several thousand ongoing
clinical trials.
Labcorp also intends to highlight IntelliGEN® Myeloid and liquid
biopsy testing for lung cancer. IntelliGEN® Myeloid is a
next-generation sequencing (NGS) assay that evaluates 50 genes
known to be useful in providing diagnostic, prognostic and
predictive information for patients with myeloid malignancies.
Liquid biopsy testing examines a blood sample for cancer cells, or
pieces of DNA from a tumor circulating in the blood, in order to
identify mutations and help select the most effective, targeted
treatments. It is an increasingly viable, non-invasive testing
option in cases where obtaining a tissue sample may be difficult or
risky.
Labcorp Drug Development will contribute two online abstracts to
the scientific program—e18608: “Mortality in adult patients with
solid or hematological cancers and SARS-CoV-2 infection with a
specific focus on lung and breast malignancies: A systematic review
and meta-analysis,” and e13584: “The role of digital clinical
measures in improving cancer care and research.”
Labcorp has also made a donation to Conquer Cancer®, the ASCO
foundation dedicated to conquering cancer throughout the world by
funding breakthrough research and sharing cutting-edge
knowledge.
To learn more about Labcorp’s new oncology platform visit us at
https://oncology.labcorp.com/.
About Labcorp
Labcorp is a leading global life sciences company that provides
vital information to help doctors, hospitals, pharmaceutical
companies, researchers, and patients make clear and confident
decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With more than
70,000 employees, we serve clients in more than 100 countries.
Labcorp (NYSE: LH) reported revenue of $14.0 billion in FY2020.
Learn about Labcorp at www.Labcorp.com, or follow us on LinkedIn
and Twitter @Labcorp.
1 The Industry Expert Theater sessions and Labcorp’s
presentation Reimagining Precision Medicine Throughout a Patient's
Journey are not official presentations of the 2021 ASCO Annual
Meeting, are not sponsored, endorsed, or accredited by ASCO, and
are not CME‐ accredited.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210602006067/en/
Labcorp Contacts: Media: Christopher Allman-Bradshaw –
336-436-8263 Media@Labcorp.com
Investors: Chas Cook – 336-436-5076 Investor@Labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2024 to May 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From May 2023 to May 2024